Compare First Solar, Inc. (FSLR) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Illumina, Inc. — how do they compare? First Solar, Inc. trades at $212.67 (market cap $24.05B), while Illumina, Inc. trades at $189.36 (market cap $28.32B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals.
| FSLR | ILMN | |
|---|---|---|
Market Cap | $24.05B | $28.32B |
Sector | Technology | Health |
52-Week High | $318.30 | $194.33 |
52-Week Low | $166.82 | $91.00 |
Enterprise Value | $22.21B | $29.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $213.15, down 3.37% amid bearish technical signals and class action lawsuit headlines. The stock shows strong fundamentals with a P/E of 14.46, net income margin of 30.73%, and robust cash flow growth, though recent earnings misses and legal overhangs weigh on sentiment. Revenue climbed to $5.22B in 2025, with projected growth to $5.4B in 2026, supported by expanding operating cash flows.
The outlook balances solid profitability and analyst bullishness (60% buy ratings, $275.17 target) against near-term legal risks and technical weakness. Upside hinges on lawsuit resolution and execution of growth forecasts, while downside risks include prolonged litigation and competitive pressures in solar tech.
Illumina (ILMN) trades at $188.27, down 1.53% on the day, yet maintains a strong technical and fundamental posture. The stock is in a bullish trend, supported by consistent earnings beats, robust profitability margins, and positive analyst sentiment. Recent news highlights strong momentum in 2026, driven by sequencing demand and new product launches, positioning the company for growth despite competitive pressures.
The outlook for ILMN is positive, with earnings growth and market leadership in genomics offering upside potential. Key risks include intensifying competition from new entrants like Roche and execution challenges in a dynamic healthcare landscape. Investor sentiment remains buoyant, but vigilance on competitive threats and margin sustainability is warranted for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
